Orrick advised OKYO Pharma on the deal.OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
